Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-048287
Filing Date
2024-04-25
Accepted
2024-04-25 16:05:13
Documents
4
Period of Report
2024-06-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A nmra_-_2024_proxy_-_def1.htm DEF 14A 725029
2 GRAPHIC img218924107_0.jpg GRAPHIC 37470
3 GRAPHIC img218924107_1.jpg GRAPHIC 85873
4 GRAPHIC img218924107_2.jpg GRAPHIC 79856
  Complete submission text file 0000950170-24-048287.txt   1006399
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41802 | Film No.: 24876176
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)